3761 related articles for article (PubMed ID: 7186736)
1. [Oncogenicity of reconstituted cells].
Koura M
Igaku Kenkyu; 1982 Dec; 52(6):289-303. PubMed ID: 7186736
[No Abstract] [Full Text] [Related]
2. The management of pigmented lesions of the nail bed.
Glat PM; Spector JA; Roses DF; Shapiro RA; Harris MN; Beasley RW; Grossman JA
Ann Plast Surg; 1996 Aug; 37(2):125-34. PubMed ID: 8863970
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic node dissections in malignant melanoma.
Karakousis CP
Ann Surg Oncol; 1998 Sep; 5(6):473-82. PubMed ID: 9754754
[TBL] [Abstract][Full Text] [Related]
4. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.
Hatva E; Kaipainen A; Mentula P; Jääskeläinen J; Paetau A; Haltia M; Alitalo K
Am J Pathol; 1995 Feb; 146(2):368-78. PubMed ID: 7856749
[TBL] [Abstract][Full Text] [Related]
5. Synergistic enhancement of nitrite on lysophospholipid-mediated cytolysis.
Kanematsu M; Takagi K; Suketa Y
Biol Pharm Bull; 1994 Jan; 17(1):78-81. PubMed ID: 8148820
[TBL] [Abstract][Full Text] [Related]
6. [Cowden's syndrome].
Krasovec M; Elsner P; Burg G
Hautarzt; 1995 Jul; 46(7):472-6. PubMed ID: 7672986
[TBL] [Abstract][Full Text] [Related]
7. Cellular immunotherapy of cancer.
Yang JC
Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and toxicity of cisplatin analogs.
Rose WC; Schurig JE; Huftalen JB; Bradner WT
Cancer Treat Rep; 1982 Jan; 66(1):135-46. PubMed ID: 7198010
[No Abstract] [Full Text] [Related]
9. Immunophenotypic characterization of tumor infiltrating lymphocytes and peripheral blood lymphocytes isolated from melanomatous and non-melanomatous Sinclair miniature swine.
Morgan CD; Measel JW; Amoss MS; Rao A; Greene JF
Vet Immunol Immunopathol; 1996 Dec; 55(1-3):189-203. PubMed ID: 9014317
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
11. Reliability of skin biopsy pathology.
Boiko PE; Piepkorn MW
J Am Board Fam Pract; 1994; 7(5):371-4. PubMed ID: 7810353
[TBL] [Abstract][Full Text] [Related]
12. Ohioensins and pallidisetins: novel cytotoxic agents from the moss Polytrichum pallidisetum.
Zheng GQ; Ho DK; Elder PJ; Stephens RE; Cottrell CE; Cassady JM
J Nat Prod; 1994 Jan; 57(1):32-41. PubMed ID: 7512623
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
[TBL] [Abstract][Full Text] [Related]
14. Involvement of peanut agglutinin-binding sugar chains in experimental metastasis of B16 melanoma cells.
Ota T; Kohno H; Maeda M; Tanino M; Odashima S
Oncol Res; 1993; 5(6-7):235-43. PubMed ID: 8123943
[TBL] [Abstract][Full Text] [Related]
15. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.
van den Oord JJ; Paemen L; Opdenakker G; de Wolf-Peeters C
Am J Pathol; 1997 Sep; 151(3):665-70. PubMed ID: 9284814
[TBL] [Abstract][Full Text] [Related]
16. Serum S100--a marker for disease monitoring in metastatic melanoma.
Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
[TBL] [Abstract][Full Text] [Related]
17. Whole-limb irradiation of the lower calf using a six-field electron technique.
Wooden KK; Hogstrom KR; Blum P; Gastorf RJ; Cox JD
Med Dosim; 1996; 21(4):211-8. PubMed ID: 8985926
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1-mediated H2O2 production by hepatic sinusoidal endothelium in response to B16 melanoma cell adhesion.
Anasagasti MJ; Alvarez A; Avivi C; Vidal-Vanaclocha F
J Cell Physiol; 1996 May; 167(2):314-23. PubMed ID: 8613473
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of interleukin-2-induced defective polymorphonuclear chemotaxis by TNF inhibitor.
Fossat C; Sainty D; Stoppa AM; Blaise D; David M; Maraninchi D; Juhan-Vague I
Eur J Haematol; 1993 Jul; 51(1):13-7. PubMed ID: 8348939
[TBL] [Abstract][Full Text] [Related]
20. Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy.
Clementi E; Bucci E; Citterio G; Landonio G; Consogno G; Fortis C
Cancer Immunol Immunother; 1994 Sep; 39(3):167-71. PubMed ID: 7923246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
